Taek-Jin Lee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Taek-Jin Lee has a total of 132 co-authors. Here are the top co-authors by number of shared publications:
- Byung Wook Eun
Department of Pediatrics, Nowon Eulji University Hospital, Seoul, Korea
13 shared publications - Eun Hwa Choi
Department of Pediatrics, Chungnam National University Hospital, Daejeon, Korea
10 shared publications - Su Eun Park
Department of Pediatrics, Pusan National University Children’s Hospital, Pusan National University School of Medicine, Yangsan, Korea
10 shared publications - Dae Sun Jo
Department of Pediatrics, Jeonbuk National University Medical School, Jeonju, Korea
9 shared publications - Yae-Jean Kim
Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, Seoul, Republic of Korea
9 shared publications - Hyunju Lee
Department of Pediatrics, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Republic of Korea
8 shared publications
Latest Publications
- Open Access
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Etiology of pediatric community-acquired pneumonia across Mycoplasma pneumoniae epidemic periods
- 25 August 2026
- Published by Springer Nature in Scientific Reports
Open AccessEtiology of pediatric community-acquired pneumonia across Mycoplasma pneumoniae epidemic periods
- Open Access
- 15 January 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (1) , 76-83
Recommendation for use of 15- and 20-valent pneumococcal conjugate vaccines in Korean infants and children
Pneumococcal disease remains the leading cause of morbidity in young children worldwide. Recent advances have expanded pneumococcal conjugate vaccines (PCVs) beyond 13-valent (PCV13) to 15-valent (PCV15) and 20- valent (PCV20) vaccines, which add 2 and 7 serotypes, respectively, thereby broadening their potential protective effects against invasive pneumococcal disease (IPD). Although policies vary among countries, Korea incorporated PCV15 and PCV20 into its National Immunization Program for children in April 2024 and October 2025, respectively, an implementation that is considered within the context of global epidemiology and policy trends. This review discusses evidence of the immunogenicity and safety of PCV15 and PCV20 from clinical trials and early postlicensure data, examines the serotype distribution and IPD burden in Korea alongside data from other regions, and summarizes vaccination recommendations for healthy and high-risk pediatric populations, including considerations for catch-up, interchangeability, and their coadministration. By integrating national updates and global evidence, this review aims to support clinicians and policymakers worldwide optimizing pneumococcal vaccination strategies for children.
- 15 January 2026
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 69 (1) , 76-83
Open AccessRecommendation for use of 15- and 20-valent pneumococcal conjugate vaccines in Korean infants and children
Pneumococcal disease remains the leading cause of morbidity in young children worldwide. Recent advances have expanded pneumococcal conjugate vaccines (PCVs) beyond 13-valent (PCV13) to 15-valent (PCV15) and 20- valent (PCV20) vaccines, which add 2 and 7 serotypes, respectively, thereby broadening their potential protective effects against invasive pneumococcal disease (IPD). Although policies vary among countries, Korea incorporated PCV15 and PCV20 into its National Immunization Program for children in April 2024 and October 2025, respectively, an implementation that is considered within the context of global epidemiology and policy trends. This review discusses evidence of the immunogenicity and safety of PCV15 and PCV20 from clinical trials and early postlicensure data, examines the serotype distribution and IPD burden in Korea alongside data from other regions, and summarizes vaccination recommendations for healthy and high-risk pediatric populations, including considerations for catch-up, interchangeability, and their coadministration. By integrating national updates and global evidence, this review aims to support clinicians and policymakers worldwide optimizing pneumococcal vaccination strategies for children.
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Seasonal Circulation of Enterovirus D68 in Korean Children, 2023–2025
Yun KW, et al. J Korean Med Sci. 2026 Dec;41:e334. https://doi.org/10.3346/jkms.2026.41.e334
- 1 January 2026
- Published by XMLink in Journal of Korean Medical Science
- Vol. 41
Open AccessSeasonal Circulation of Enterovirus D68 in Korean Children, 2023–2025
Yun KW, et al. J Korean Med Sci. 2026 Dec;41:e334. https://doi.org/10.3346/jkms.2026.41.e334
- Open Access
- 15 October 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (10) , 742-750
Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent RSV-associated LRTI among infants and young children. Nirsevimab was launched in Korea in February 2025. This report summarizes the recommendations of the Committee on Infectious Diseases of the Korean Pediatric Society regarding the use of nirsevimab. We recommend a single dose of nirsevimab for all neonates born during the RSV season (October to March), as well as all infants younger than 6 months at the start of the RSV season (i.e., those born between April and September of that year). Nirsevimab should be administered shortly after birth (within the first week of life) to neonates born during the RSV season and just before or early in the season (late September to October) to infants entering their first RSV season. Nirsevimab may also be considered for children younger than 2 years of age who are at increased risk of severe RSV disease and entering their second RSV season.
- 15 October 2025
- Published by Korean Pediatric Society in Clinical and Experimental Pediatrics
- Vol. 68 (10) , 742-750
Open AccessRecommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children
Respiratory syncytial virus (RSV) is a leading cause of acute lower respiratory tract infections (LRTIs) in infants and young children. In April 2024, the Korea Ministry of Food and Drug Safety approved nirsevimab (Beyfortus), a long-acting monoclonal antibody, as a passive immunization to prevent RSV-associated LRTI among infants and young children. Nirsevimab was launched in Korea in February 2025. This report summarizes the recommendations of the Committee on Infectious Diseases of the Korean Pediatric Society regarding the use of nirsevimab. We recommend a single dose of nirsevimab for all neonates born during the RSV season (October to March), as well as all infants younger than 6 months at the start of the RSV season (i.e., those born between April and September of that year). Nirsevimab should be administered shortly after birth (within the first week of life) to neonates born during the RSV season and just before or early in the season (late September to October) to infants entering their first RSV season. Nirsevimab may also be considered for children younger than 2 years of age who are at increased risk of severe RSV disease and entering their second RSV season.
- Open Access
- 3 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 162-170
Diagnostic Accuracy of Serological Tests for Mycoplasma pneumoniae Infections in Children with Pneumonia, Based on Symptom Onset
Gahee Kim, M.D., Ki Wook Yun, M.D., Ph.D., Dayun Kang, M.D., Taek Jin Lee, M.D., Byung Wook Eun, M.D., Ph.D., Hyunju Lee, M.D., Ph.D., Yae-Jean Kim, M.D., Ph.D., Doo Ri Kim, M.D., Ph.D., Areum Shin, M.D., Hyun Mi Kang, M.D., Ph.D., Ye Ji Kim, M.D., Ph.D., Byung Ok Kwak, M.D., Ph.D., Younghee Lee, M.D., Ye Kyung Kim, M.D., Ph.D., Young June Choe, M.D., Ph.D., Woosuck Suh, M.D., Kyo Jin Jo, M.D., Kyung-Ran Kim, M.D., Eun Young Cho, M.D., Ph.D., Kyung Min Kim, M.D., Joon Kee Lee, M.D., Ph.D., and Su Eun Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0125
- 3 September 2025
- Published by Annals of Laboratory Medicine in Annals of Laboratory Medicine
- Vol. 46 (2) , 162-170
Open AccessDiagnostic Accuracy of Serological Tests for Mycoplasma pneumoniae Infections in Children with Pneumonia, Based on Symptom Onset
Gahee Kim, M.D., Ki Wook Yun, M.D., Ph.D., Dayun Kang, M.D., Taek Jin Lee, M.D., Byung Wook Eun, M.D., Ph.D., Hyunju Lee, M.D., Ph.D., Yae-Jean Kim, M.D., Ph.D., Doo Ri Kim, M.D., Ph.D., Areum Shin, M.D., Hyun Mi Kang, M.D., Ph.D., Ye Ji Kim, M.D., Ph.D., Byung Ok Kwak, M.D., Ph.D., Younghee Lee, M.D., Ye Kyung Kim, M.D., Ph.D., Young June Choe, M.D., Ph.D., Woosuck Suh, M.D., Kyo Jin Jo, M.D., Kyung-Ran Kim, M.D., Eun Young Cho, M.D., Ph.D., Kyung Min Kim, M.D., Joon Kee Lee, M.D., Ph.D., and Su Eun Park, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0125
- Open Access
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (40) , e250
Hospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016–2023 in Korea: Serotype Trends and Vaccination Policy
Kang D, et al. J Korean Med Sci. 2025 Aug;40:e250. https://doi.org/10.3346/jkms.2025.40.e250
- 1 January 2025
- Published by XMLink in Journal of Korean Medical Science
- Vol. 40 (40) , e250
Open AccessHospital-Based Surveillance of Pediatric Invasive Pneumococcal Diseases, 2016–2023 in Korea: Serotype Trends and Vaccination Policy
Kang D, et al. J Korean Med Sci. 2025 Aug;40:e250. https://doi.org/10.3346/jkms.2025.40.e250
- Open Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 329-330
Reply: Response to Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management
Kang HM, et al. Infect Chemother. 2025 May;57:e34. https://doi.org/10.3947/ic.2025.0014
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (2) , 329-330
Open AccessReply: Response to Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management
Kang HM, et al. Infect Chemother. 2025 May;57:e34. https://doi.org/10.3947/ic.2025.0014
- Top Cited PapersOpen Access
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (1) , 13-30
Pertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management
Kang HM, et al. Infect Chemother. 2024 Nov;56:e59. https://doi.org/10.3947/ic.2024.0117
- 1 January 2025
- Published by XMLink in Infection & Chemotherapy
- Vol. 57 (1) , 13-30
Top Cited PapersOpen AccessPertussis in the Post-COVID-19 Era: Resurgence, Diagnosis, and Management
Kang HM, et al. Infect Chemother. 2024 Nov;56:e59. https://doi.org/10.3947/ic.2024.0117
- Open Access
- 31 August 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (9) , 1806
Clinical Manifestations, Macrolide Resistance, and Treatment Utilization Trends of Mycoplasma pneumoniae Pneumonia in Children and Adolescents in South Korea
A resurgence of Mycoplasma pneumoniae (MP)—the leading cause of community-acquired bacterial pneumonia, particularly in children—occurred following the COVID-19 pandemic. We aimed to investigate the clinical manifestations, macrolide resistance patterns, and therapeutic approaches related to the MP pneumonia epidemic. Children and adolescents diagnosed with MP pneumonia in September–December 2023 were screened. Clinical data were retrospectively collected from 13 major hospitals using concordant microbiological criteria, including either a positive PCR result or four-fold increase in serological markers. Demographic characteristics, treatment modalities, and clinical outcomes were analyzed. Of the 474 screened patients, 374 (median age: 7.7 [IQR, 5.4–9.6] years; hospitalization rate: 88.6%) met the microbiological confirmation criteria. Most patients experienced fever (98.9%), and lobular/lobar consolidation (59.1%) was the dominant radiological finding. The macrolide resistance rate remained high at 87.0%; corticosteroids were widely used (55.6%) alongside macrolides, despite resistance. Patients with consolidation had prolonged fever (median 8 vs. 7 days, p = 0.020) and higher hospitalization rates (92.3% vs. 83.0%, p = 0.008). Macrolide resistance did not significantly influence radiological outcomes. This study highlights the ongoing challenge of macrolide resistance in MP pneumonia and need for tailored therapeutic approaches. Despite high resistance, macrolides remain commonly prescribed, often concurrently with corticosteroids.
- 31 August 2024
- Published by MDPI AG in Microorganisms
- Vol. 12 (9) , 1806
Open AccessClinical Manifestations, Macrolide Resistance, and Treatment Utilization Trends of Mycoplasma pneumoniae Pneumonia in Children and Adolescents in South Korea
A resurgence of Mycoplasma pneumoniae (MP)—the leading cause of community-acquired bacterial pneumonia, particularly in children—occurred following the COVID-19 pandemic. We aimed to investigate the clinical manifestations, macrolide resistance patterns, and therapeutic approaches related to the MP pneumonia epidemic. Children and adolescents diagnosed with MP pneumonia in September–December 2023 were screened. Clinical data were retrospectively collected from 13 major hospitals using concordant microbiological criteria, including either a positive PCR result or four-fold increase in serological markers. Demographic characteristics, treatment modalities, and clinical outcomes were analyzed. Of the 474 screened patients, 374 (median age: 7.7 [IQR, 5.4–9.6] years; hospitalization rate: 88.6%) met the microbiological confirmation criteria. Most patients experienced fever (98.9%), and lobular/lobar consolidation (59.1%) was the dominant radiological finding. The macrolide resistance rate remained high at 87.0%; corticosteroids were widely used (55.6%) alongside macrolides, despite resistance. Patients with consolidation had prolonged fever (median 8 vs. 7 days, p = 0.020) and higher hospitalization rates (92.3% vs. 83.0%, p = 0.008). Macrolide resistance did not significantly influence radiological outcomes. This study highlights the ongoing challenge of macrolide resistance in MP pneumonia and need for tailored therapeutic approaches. Despite high resistance, macrolides remain commonly prescribed, often concurrently with corticosteroids.
- Open Access
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (47) , e401
A Report on a Nationwide Surveillance System for Pediatric Acute Hepatitis of Unknown Etiology in Korea
Lee KJ, et al. J Korean Med Sci. 2023 Nov;38:e401. https://doi.org/10.3346/jkms.2023.38.e401
- 1 January 2023
- Published by XMLink in Journal of Korean Medical Science
- Vol. 38 (47) , e401
Open AccessA Report on a Nationwide Surveillance System for Pediatric Acute Hepatitis of Unknown Etiology in Korea
Lee KJ, et al. J Korean Med Sci. 2023 Nov;38:e401. https://doi.org/10.3346/jkms.2023.38.e401